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Abstract 
Statistics show a high prevalence of metabolic syndrome (MetS) in patients with mental 
illness receiving second-generation antipsychotic medications. MetS is associated with 
elevation of obesity, truncal obesity, blood pressure, cholesterol, and fasting glucose.  
The purpose of this project was to educate psychiatric providers about the importance of 
MetS screening, early detection, management, and referral for better treatment and 
management. The project was guided by Lewin’s theory of change model. The project 
inquired if educational intervention on MetS improved providers’ knowledge and intent 
to adopt MetS guidelines. A literature review and established guidelines of the American 
Psychiatric Association and American Diabetic Association about MetS in psychiatric 
patients directed the educational content. Five expert panelists with over 10 years of 
experience in psychiatric mental health reviewed the educational content using a Likert-
type questionnaire. Findings resulted in the acceptance of the educational content without 
further recommendation. Twelve staff attended the educational session presented on 
MetS. Comparison of the pretest and posttest questionnaires that has 5 multiple choice 
questions indicated some positive effects. The good knowledge of MetS, how to screen 
for MetS, health promotion activities with consumers, metabolic profile of different 
neuroleptic medications, providers’ roles in MetS. The participants’ overall knowledge 
about MetS screening improved from 8.3% pretest to 83.3% after receiving the 
educational program. The educational project for MetS screening might foster positive 
social change by improving continuity and quality of care, which will lead to better 
patient outcomes, reduce healthcare cost, and impact positive patient outcomes. 
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Section 1: Nature of the Project 
Introduction  
Patients with chronic mental illness are treated with both first-generation 
antipsychotic medications (FGAs) and second-generation antipsychotic medications 
(SGAs). The use of psychotropic medications illustrates an essential part of psychiatric 
practice. Antipsychotic medications are used in the treatment of mental disorders other 
than psychosis, such as bipolar, depression, and anxiety. The use of these antipsychotic 
medications has increased the ability of psychiatric providers to treat psychiatric ailments 
with tolerable side effects but has given rise to metabolic syndrome (MetS) among 
patients with mental illness. The World Health Organization (WHO) has recognized 
MetS as a global epidemic and a major public health problem (Ho, Zhang, Mak, & Ho, 
2014). Its associated complications are affecting a large number of people. According to 
Moore et al. (2017), with the definition of MetS by the International Diabetes Federation 
(IDF) and the National Cholesterol Education program, the prevalence of MetS is 
estimated at more than 30% in the United States. 
Patients with mental illness have an increased risk of developing MetS compared 
to the general population (Arms, Bostic, & Cunningham, 2014). MetS is a complication 
related to antipsychotic medications used in this vulnerable population. It is considered to 
be underdiagnosed and undertreated in psychiatric patients. MetS is associated with 
chronic mild inflammation; elevation of obesity, truncal obesity, blood pressure, 
cholesterol, and fasting glucose; and increased risk for obesity and truncal obesity, all of 
which lead to cardiovascular disease and/or diabetes (Cunningham, Riano, & Mangurian, 
2 
 
2018; Kioko, Williams, & Newhouse, 2016). Any three of the five components are 
necessary for diagnosis (Saloojeel, Burns, & Motala, 2014). According to the American 
Heart Association, the rate of MetS in the general population is 34% compared to 55%–
60% in mentally ill patients taking antipsychotic medications (Arms, Bostic, & 
Cunningham, 2014). MetS can lead to chronic diseases, such as heart disease and 
diabetes, which are responsible for seven out of 10 deaths among Americans each year 
and account for 75% of the nation’s healthcare spending (CDC, 2017).  
The purpose of this scholarly project is to educate nursing staff and psychiatric 
providers about the importance of metabolic monitoring, screening, early detection, 
management, and referral of patients to primary care providers for appropriate treatment 
and management. Educating nursing staff about MetS and associated complications will 
lead to nurses communicating these physical health challenges to patients and 
encouraging them to keep medical appointments in order to manage the ailments 
properly. The educational intervention will foster social changes through education of 
psychiatric providers in order to make a positive impact both physically and mentally on 
this vulnerable population.  
Problem Statement 
MetS is a clustering of cardiovascular risk factors including dyslipidemia, 
abdominal obesity, hypertension, and hyperglycemia (Penninx & Lange, 2018). MetS is a 
complex, noncommunicable, multiple systems disorder (Cotes et al., 2015). It has 
become a serious comorbidity among patients with mental illness. Cotes et al. (2015) 
noted that in November 2003, the North American Association for the Study of Obesity, 
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American Psychiatric Association (APA), American Diabetes Association (ADA), and 
American Association of Clinical Endocrinologists held a conference on antipsychotic 
medications and diabetes.  
Based on the conference outcome, a class warning was implemented by the APA, 
the ADA, and the U.S. Food and Drug Administration related to the risk for diabetics and 
recommendations were issued for glucose and lipid monitoring with SGA medications 
(Morrato et al., 2016). Because of the increased morbidity in this population, psychiatric 
patients taking antipsychotic medications should be screened with the same rate or even 
more frequently than patients in the general population. Saloojeel et al. (2014) noted that 
these agencies developed a general agreement that established a MetS baseline screening 
and monitoring for patients taking antipsychotic medications, mainly SGAs. 
I conducted a needs assessment in an in-patient psychiatric center located in the 
Midwestern United States to determine the adherence of practice guidelines for MetS 
screening by psychiatric providers. The assessment analysis indicated that the gap in 
practice was lack of metabolic monitoring and screening among patients taking 
antipsychotic medications. Regardless of the global consensus for MetS screening, the 
rate of testing remains poor despite the relationship between MetS and antipsychotic 
medications (Happell, Platania-Phung, Gaskin, & Stanton, 2016; Kioko et al., 2016; 
Munshi, Patel, Mazhar, Hassan, & Siddiqui, 2015). In spite of best practice 
recommendations, psychiatrists practicing in this setting were not screening for MetS in 
their patients taking antipsychotic medications.  
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To address the healthcare gap in practice, providers’ adherence to MetS 
guidelines can lead to early identification of treatable metabolic risk conditions, 
management, referrals for treatment, improvement in patient quality of life, and reduction 
in healthcare costs. I believe that nursing staff are in the position to lead the way in 
metabolic control by educating identified patients about behavior changes and healthy 
life choices to enhance physical health and associated complications. The guideline 
recommends baseline monitoring at the initiation of an SGA, 3 months later, and 
annually thereafter. This scholarly project on educating psychiatric physicians and nurses 
has the ability to implement the recommended guidelines and to improve the care 
provided to people with mental illness taking SGAs.  
Purpose 
Antipsychotic medications are used in the treatment of mental disorders other 
than psychosis, such as bipolar, depression, and anxiety, because of fewer side effects 
associated with atypical antipsychotics. There is a long history of using antipsychotic 
medications in the treatment of other health problems with or without psychosis. MetS is 
one of the undesirable side effects associated with antipsychotic medications. Despite the 
benefits of an established protocol and screening tool to monitor MetS, there are 
healthcare disparities in screening and treatment of MetS among patients with mental 
illness. It should be a realistic expectation for psychiatric providers who prescribe 
antipsychotic medications to collaborate with family practice providers to facilitate 
appropriate monitoring and treatment for better patient health outcomes.  
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The focus of this project is to improve the knowledge of healthcare providers on 
the metabolic guidelines for screening, early intervention, and treatment among 
psychiatric patients. The goal is to improve patient care by increasing the knowledge of 
providers to adopt the best clinical practice guidelines for early detection and treatment of 
MetS in this vulnerable population. 
The practice focused question is: Does an educational intervention for psychiatric 
providers prescribing psychiatric medications improve their knowledge and intent to 
adopt and implement metabolic screening guidelines in practice?  
Nature of the Doctoral Project  
I used several databases for the literature review for this project: MEDLINE, Pub 
Med, CINAHL, Google Scholar, and ProQuest. The keywords included in the search 
were metabolic syndrome, antipsychotic medications, metabolic screening, and mental 
illness. To meet inclusion criteria, the articles chosen were published in the English 
language in scholarly, peer-reviewed publications within the past 5 years. I reviewed 
guidelines from the ADA, APA, NACE, and North American Association for the Study 
of Obesity as well.  
The setting for the scholarly project is a stand-alone local psychiatric in-patient 
center in the Midwest. The psychiatric center offers comprehensive inpatient psychiatric 
services for adolescents, adults, and seniors. The center is staffed by registered nurses 
(RNs), three advanced psychiatric nurse practitioners, and three psychiatrists. This 
scholarly project was implemented as in-service education for psychiatric providers, 
including the RNs, nurse practitioners, psychiatrists, the chief nursing officer, and the 
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medical director. I developed the educational materials and then presented to an expert 
panel to evaluate the appropriateness of the materials for the staff. The chief nursing 
officer and quality assurance manager gave approval to design and implement a 1-hour 
educational session with the healthcare team about the ADA recommendations for MetS 
screening in patients taking SGAs. 
The project question helped to organize the more useful literature search results 
and contributed clear guidance in the process of planning, implementing, and evaluating a 
practice change in a clinical setting (Curtis, Fry, Shaban, & Considine, 2016). The goal of 
staff education is to improve patient care outcomes and achieve a standard of practice. A 
30-minutes presentation along with a basic educational pamphlet (see Appendix A) about 
MetS, educational intervention objective (see Appendix B), and the ADA/APA consensus 
guidelines (see Appendix C) were provided to the team. The M-BACK (pretest and 
posttest) questionnaire (see Appendix D) assessed improvement in knowledge. The M-
BACK is a reliable measure used to assess the effectiveness of interventions aimed at 
increasing uptake of metabolic monitoring (Watkins et al., 2017). An additional question 
was added to the posttest to ascertain respondents’ likelihood of implementing MetS 
screening. Before the educational intervention, the participants completed an anonymous 
knowledge pretest. At the end of the educational intervention, the participants completed 
the posttest survey (see Appendix E) anonymously.  
Significance 
The goal of the scholarly project is to improve the knowledge of healthcare 
providers on the metabolic guidelines for screening, early intervention, and treatment 
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among psychiatric providers prescribing antipsychotic medications. The identified 
stakeholders in this project are the mentally ill patients on antipsychotic medications, the 
psychiatric providers, the nursing staff, and finally the leadership and policymakers that 
influence change in the hospital. The scholarly project will affect different stakeholders 
directly and indirectly. The identified stakeholders affected by the scholarly project were 
the psychiatric providers with prescriptive authority, the nursing staff, and the  
policymakers. The scholar believes that involving the stakeholders is crucial to the 
designing and implementation of a successful project. In the case of MetS screening and 
monitoring, involving the front-line nurses who will be the ones completing the vital 
signs and lab work is imperative. Empowering the frontline nurses to take ownership of 
the program is vital for the success of the project. The long-term benefit of monitoring 
MetS is for improved health outcomes, wellness, and, reduction in mortality and 
morbidity among psychiatric patients taking antipsychotic medications. 
Significance to Nursing Practice 
Mental illness is not only viewed per severity of the symptoms that are presented 
by the individual, it is also how the symptoms lead to impairment in the individual’s 
functional ability. Antipsychotic medications noted as the FGAs developed in the 1950s 
are the first generation of drugs proven to be effective in treating psychiatric symptoms 
and are also used to treat other comorbid psychotic illnesses while SGAs emerged in the 
1980s (AHRQ, 2015). Each class of antipsychotic medications has considerable overlap 
between them even though they have distinct side-effects profile. According to the 
Agency for Healthcare Research and Quality (2015), FGAs are effective in treating 
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psychosis but do not adequately improve symptoms of diminished emotional expression, 
such as avolition, alogia, and asociality. The FGA medications also produce significant 
extrapyramidal side effects such as akathisia, tardive dyskinesia, and neuroleptic 
malignant syndrome hyperprolactinemia, avolition, alogia, and anhedonia (AHRQ, 
2015). Avolition which means a decrease in motivation. Alogia is diminished speech an 
output. Anhedonia is a decrease in the ability to experience a pleasure. Neuroleptic 
malignant syndrome (NMS), is a rare but life-threatening side effect of antipsychotic 
medication with symptoms of high fever, confusion, rigid muscles, variable blood 
pressure, sweating and increased heart rate (Hosseini & Elyasi, 2017). 
The atypical antipsychotic medications known as SGAs have a significant 
advantage over FGAs and are more efficacious in treating psychiatric symptoms with 
more tolerable side effect profiles, improves negative symptoms, and causes less 
extrapyramidal symptoms (Xiang, Ungvari, Correll, Chiu, & Shinfuku, 2016). Even 
though the medications are known for their efficaciousness, they trigger weight gain, 
affect blood glucose and lipid levels, and eventually lead to MetS.  
MetS increases among psychiatric patients taking second- generation 
antipsychotic (SGAs) medications and increases their risks for physical health issues 
including cardiovascular disease, leading to premature morbidity and mortality. The high 
mortality rate observed in psychiatric patients is due to comorbid health problems related 
to diabetes, stroke, and obesity and all point to MetS. Both atypical and typical 
antipsychotic medications have significant risks for MetS in people taking these 
medications. However, this monitoring is often neglected, putting these individuals at risk 
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for life-threatening complications. Yet, metabolic screening and monitoring remain low 
among psychiatric patients on antipsychotic medications putting these individuals at risk 
for life-threatening complications. As psychiatric providers prescribe antipsychotic 
medications known to have a connection with negative physical health outcomes, there is 
a need for them to be proactive and incorporate physical health treatment into their daily 
routine.  
In today’s healthcare delivery, there is a push to make 90% of clinical decisions 
based on best available evidence by 2020 (Warren, et al, 2016). To improve patient safety 
and quality of care, it is imperative for nurses to create a culture of evidence-based 
practice and base clinical decisions on evidence. Implementation of metabolic monitoring 
will improve patient outcomes by closing the gap between evidence and implementation 
in a clinical setting. Nurses are the frontline staff and have the potential to influence and 
shape healthcare systems in the country. Studies have shown that MetS is associated with 
an increased rate of deaths, decreased health outcomes and reduced lifespans among 
patients with chronic mental illness. Nurses should take the lead in educating psychiatric 
patients about healthy lifestyles that could reduce the risk of development of MetS, and 
improve their overall health. Nursing should understand that long-term effects of lack of 
metabolic monitoring include increased cost of healthcare spending, morbidity, mortality 
rate, chronic illnesses and decreased productivity of the workforce. With the evidence 
about MetS more common among psychiatric patients, there is a need to consider 
diagnosis and treatment of Mets concurrently with the management of psychiatric 
conditions (Penninx & Lange, 2018).  
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Implications for Social Change 
Studies have shown that MetS is prevalent among psychiatric patients. As a result, 
there is a need to consider diagnosis and treatment of MetS simultaneously with the 
treatment of psychiatric condition in this population. Cunningham and colleagues (2018) 
found that metabolic monitoring aims to address these health disparities by screening for 
metabolic parameters and identifying abnormalities so that appropriate interventions will 
be implemented. Screening and monitoring of MetS among patients on antipsychotic 
medications will not only hinder complexity but will also prevent complications 
associated with the illness, improve patient outcome, quality of care and promote positive 
social change. Adherence to metabolic monitoring guidelines treatment will improve 
continuity and quality of care, which will lead to better patient outcomes, increased 
healthcare productivity, and cost effective for United State healthcare system and finally 
impact positive patient outcomes in the field of psychiatry. This is alignment with 
Walden University’s mission of applying research to solve the programs in the world 
(Walden Report, 2017).  
Summary 
MetS is an emerging problem in healthcare among psychiatric patients taking 
antipsychotic medications. MetS is a major and escalating public health challenges 
worldwide. The combination of symptoms of high blood pressure, high cholesterol, high 
fasting glucose, and truncal obesity that lead to cardiovascular disease and/or a type of 
diabetes are associated with Mets. The major contributors to MetS are diabetes mellitus 
and hypertension, which are worldwide healthcare problems that affect millions of 
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people. The American Diabetic Association (ADA, 2018) reports $327 billion in annual 
costs for diabetes costs, which include $237 billion in direct medical costs and $90 billion 
in reduced productivity. It is estimated that the number of Americans with prediabetes 
will climb from 90.6 million in 2015 to 107.7 million in 2030 (Rowley, Bezold, Arikan, 
Byrne, & Krohe, 2017). It is estimated that the global prevalence of diabetes is high, 382 
million people with diabetes in 2013, expected to rise to 592 million by 2035 (Forouhi & 
Wareham, 2014).  
The long-term benefit of monitoring MetS is for improved health outcomes, 
wellness, reduction in mortality and morbidity among psychiatric patients taking 
antipsychotic medications. Screening for MetS in patients with severe mental illness will 
signify an improvement in inequality in healthcare for people with mental illness 
(Happell et al., 2016). To decrease morbidity and mortality, early detection, management 
and referrals are the long-term benefits of monitoring and screening MetS in this 
vulnerable population. Section 2 will address the background and context of this 
scholarly educational project. 
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Section 2: Background and Context 
Introduction 
Antipsychotic medications are used in the treatment of mental disorders other 
than psychosis, such as bipolar, depression and anxiety, because of the fewer side effects 
associated with atypical antipsychotics. MetS is one of the undesirable side effects 
associated with SGAs. Regardless of the global consensus for screening and monitoring 
MetS, the rate of testing remains poor, despite the clear relationship between MetS and 
SGAs (Happell et al., 2016; Kioko et al., 2016; Munshi et al., 2015). In spite of best 
practice recommendations, psychiatrists practicing in this setting are not screening for 
MetS in their patients who are on antipsychotics.  
The focus of the project is to improve the knowledge of healthcare providers on 
the metabolic guidelines for screening, early intervention, and treatment among 
psychiatric providers prescribing antipsychotic medications. The goal is to improve 
patient care by increasing the knowledge of providers and their adoption of best clinical 
practice guidelines for early detection and treatment of MetS in this vulnerable 
population. The practice focused question was: Does an educational intervention for 
psychiatric providers prescribing psychiatric medications improve their knowledge and 
intent to adopt and implement metabolic screening guidelines in practice? Use of best 
practice guidelines should improve the screening rates and diagnosis/referral for MetS. 
Knowledgeable psychiatric nursing care will contribute to the adherence of patients in 
addressing self-care. 
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In the next section, I will further discuss the concepts, models, and theories; the 
relevance to nursing practice; the local background, and the role of the DNP student. 
Concepts, Models, and Theories 
The Lewin’s theory of change model of 1974 was chosen to guide this project. 
Organizational change involves the movement of an organization from its current state to 
a desired future state. Lewin’s theory supports changing a traditional pathway of 
unfreezing the current provider behaviors (movement) and reinforcing changes in 
organizational structure (refreezing). Lewin’s theory supports changing the status quo. It 
is used to comprehend how professional behaviors become accepted and continuous in 
clinical settings. The theory is a model of organizational change used to guide the design 
and implementation of the change process.  
Unfreezing is the first stage of implementation of change in an organization. The 
theory indicates that involving team members and stakeholders in implementing 
interventions and sustaining the project is critical. The transition will face less resistance 
if the stakeholders are empowered in authority and responsibility right from the planning 
phase. This is the phase of the project where I met with the stakeholders (providers, RNs, 
chief nursing officer, and the medical director) to educate them about the need for change 
and moving away from their status quo. I was the change agent who educated staff about 
the gap in practice. To gain the desired results from the proposed change, leadership 
involvement was critical; it became imperative to get their buy-in for the project. They, as 
the policy makers, established a clear vision of the change process and reinforced the 
benefits of the change to the patients. 
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The change phase was the transition phase, which included providing educational 
information on the importance of using evidence-based practice guidelines. The 
educational goal was to inform the staff about the gap in practice and the importance of 
the educational intervention and prescribers’ responsibilities to protect the cardio 
metabolic health of the patients and promote better patient outcomes for this population. 
Awareness was created about the importance of screening for MetS among patients 
taking SGAs. Communication with staff members was imperative at this level in order 
for the providers to buy into the idea. If they understood the necessity and urgency of the 
behavior, they would be more likely to be receptive toward the change agent. 
Involvement of frontline staff from planning to implementation is the most effective 
strategy for overcoming resistance to change. 
The final phase was the refreezing stage; it is also called the reinforcement phase. 
At this phase, an effort was made so that employees adopted the suggested change and 
dis not revert to their old ways. At this phase, the staff incorporated the change into their 
daily routine by monitoring patients for MetS, obtaining their vital signs, measuring 
weight and waist circumference, and obtaining basic lab work. Once MetS were 
identified, the providers/nurses should implement care and collaborate with family 
practice providers to facilitate appropriate primary care to decrease complications of 
chronic illness and reduce the rate of morbidity and mortality. 
Key Concepts and Definitions 
Table 1 illustrates the defining criteria of MetS according to National Cholesterol 
Education Program Adult Treatment Panel and IDF (Sulistiowati & Sihombing, 2016).  
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Table 1 
 
Defining Criteria of Metabolic Syndrome 
Criteria Defining levels 
Abdominal obesity 
Men 
Women 
Waist circumference 
Greater than or equal to 102 cm (greater than 40 inches) 
Greater than or equal to 88 cm (greater than 35 inches) 
Triglycerides Greater than or equal to 150 mg (1.7 mmol/L) 
Or on medicines for the management of abnormal triglycerides 
HDL cholesterol 
Men 
Women 
Greater than 40 mg/dl 
Greater than 50mg/dl 
Or on medications for the control of abnormal cholesterol 
Blood pressure Greater than or equal to 130/85 mmHg 
Or on medications for the management of abnormal blood 
pressure 
Fasting blood 
glucose 
Greater than or equal to 110mg/dl 
Or on medicines for the management of abnormal blood 
glucose 
 
Relevance to Nursing Practice 
Ward et al. (2018) noted that poor health outcomes of people with mental illness 
are high, which reduces life expectancy by 17 years when compared to the general 
population. The life expectancy of people with mental illness is 25 to 30 years less than 
the general population (Pena, DeJongh, Haas, & Harms, 2018). According to Liu et al. 
(2017), the high mortality in patients suffering from mental illness is largely caused by 
preventable and treatable long-term diseases, especially cardiovascular disease. The 
adverse metabolic effects of atypical antipsychotics induce more weight gain and 
metabolic abnormalities. People with mental illness were 30% less likely to have their 
weight, blood glucose, and lipids assessed (Happell et al., 2016). Moreover, 20%–25% of 
the world’s adult population has MetS, with higher rates among people with mental 
illness (Kioko et al., 2016). Mangurian et al. (2016) suggested that the rates of glucose 
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monitoring (fasting blood glucose) and lipids screening are as low as 30% among patients 
taking SGAs. Gardner-Sood et al. (2015) studied 450 randomly selected participants in an 
out-patient clinic and found that a majority of patients have central obesity, half the 
sample had a body mass index greater than 30 kg/m2; 57% were diagnosed with MetS, 
and one in five met the criteria for Type 2 diabetes.  
In a global study of 311 psychiatric patients taking SGAs, only 3.9% of the 
participants had fasting glucose monitoring, 1.8% had a fasting lipid test, and 0% had 
monitoring for waist circumference (Saloojeel et al., 2014). In a study of 50 psychiatric 
patients treated with SGAs, none had been previously screened for MetS by their 
psychiatrists even though 30% were positive for diabetes, 64.4% were diagnosed with 
hypertension, and 88% had increased cholesterol (Munshi et al., 2015). In their meta-
analysis, Saloojeel et al. (2014) found that in five high-income countries (the United 
States of America, the United Kingdom, Australia, Canada, and Spain), routine baseline 
screening was above 50% for blood pressure and lipids only, while glucose and 
cholesterol were less than 50%.  
Regardless of the global established consensus, research shows that the rate of 
screening and monitoring MetS remains poor and providers continue to show inadequate 
knowledge about MetS (Kioko et al., 2016; Lui et al., 2016). Evidence shows there is a 
lack of consistency in education about MetS, which leads to lower rates of screening and 
monitoring poor health outcomes for psychiatric patients (Łopuszańska et al., 2014; 
Munshi et al., 2015).  
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Gaps in Practice 
A survey by Munshi and colleagues (2015) showed 50 psychiatric patients taking 
SGAs in a Canadian psychiatric hospital did not get screened for MetS syndrome. The 
outcome of the survey showed that the psychiatrists fail to conduct a complete MetS 
screening on the patients, even though the patients were positive for MetS. The ADA 
consensus guideline is still in place today. It still remains the responsibilities of 
psychiatric providers to follow the ADA recommended guidelines for MetS screening in 
patients taking SGAs (Gardner-Sood et al., 2015; Lopuszanska et al., 2014). Education 
still remains one of the factors for improving the rate of metabolic screening (Castillo et 
al., 2015).  
Evidenced-based practice has become the cornerstone for healthcare practice. The 
scope and standards of psychiatric nursing is defined as a holistic approach involving the 
physical, mental, psychosocial, and spiritual needs of the patients (APNA, 2014). For 
nurses to provide the best practice, they are challenged to search for the best evidence to 
support patient assessment, intervention to develop policies and to refine old ones. With 
evidence-based practice, doctorally prepared nurses are situated to fill the gap that has 
developed in the healthcare system to serve those with mental illness who are at risk of 
adverse health outcomes (Bolton, Knight, & Kopeski, 2016). The Institute of Medicine 
(IOM) noted the gap between what we know and what we do in patient care. Nurses have 
the responsibility to bridge the research-practice gap. Even though there exists a practice 
guideline for metabolic monitoring of patients with mental illness taking antipsychotic 
medications, the monitoring in low in this population. Health promotion, prevention of 
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illness, and management of chronic diseases are some of the primary functions of 
doctorate-prepared nurses according to American Nurses Association (ANA, 2017).  
The life expectancy and quality of life for people with mental illness will not 
improve if metabolic effects of antipsychotic medications go undetected. Screening for 
MetS in patients with mental illness will signify an equality in healthcare for people with 
mental illness (Happell et al., 2016). According to Cunningham and colleague (2018), 
implementation of MetS monitoring and screening addresses the health disparities among 
psychiatric patients so that appropriate interventions will be implemented for effective 
positive and social changes to improve patient outcomes. Lack of transforming guidelines 
into practice as seen in the lack of utilizing the MetS screening tool among psychiatric 
patients on SGA will prevent early diagnosis and treatment of MetS (Kioko et al., 2016). 
The project established a scholarly evidence-based project that supported the significance 
of screening and monitoring MetS in patients taking SGAs to improve patient outcomes 
by closing the gap between evidence and implementation in a clinical setting. 
Barriers to Screening and Monitoring  
Even though the evidence-based practice has shown to improve quality of care 
and patient outcomes, yet, there exist some barriers to implementation of research 
evidence in clinical practice. The application of evidence-based is not a linear process; it 
comprises many steps and relationships the between researcher and the knowledge users. 
Human beings are resistant to change in general. Change in any setting is often faced 
with resistance and can be challenging in nature. Despite the benefits of using screening 
tools to monitor MetS, barriers to screening still exit. The lack of adequate screening and 
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management of MetS is an indication that there are barriers to a successful 
implementation of the screening and monitoring of patients taking antipsychotic 
medications. There are three levels of barriers identified, which include providers, 
patients, and hospital.  
Providers’ Barriers 
One of the major reasons associated with providers’ barriers in the 
implementation of MetS screening and monitoring according to the established guideline 
is the inadequate knowledge about the screening. It was important that the healthcare 
providers became conversant with about the metabolic screening and monitoring process. 
Munshi and colleagues (2015) noted that psychiatric providers are not trained to provide 
basic primary care to psychiatric patients. Pena, DeJongh, Haas, & Harms (2018) stated 
that psychiatric providers have inadequate knowledge and awareness about the risk of 
MetS associated with SGAs. According to McKenna and colleagues (2014), there exists 
some confusion regarding who is responsible for screening MetS. Edelsohn and 
colleagues (2015), found that metabolic monitoring can be affected by a lack of obvious 
designated responsibility for recognizing and managing physical health problems and 
lack of integrated services.  
Some psychiatric providers believed that it is not within their scope of practice to 
screen and manage MetS, while PCPs stated it was the responsibility of the psychiatric 
providers to monitor MetS in psychiatric patients. Another vital factor identified by 
psychiatric providers’ poor adherence to established guidelines was an insufficient 
provider time in performing the assessment, interpreting lab values and educating patients 
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(Jeffrey, 2015). Poor communication between mental healthcare providers and primary 
care providers can lead to negative health outcomes associated with poor laboratory 
monitoring (Edelsohn, Parthasarathy, Terhorst, Karpov, & Schuster, 2015). 
In a study by Mangurian and colleagues (2013), over 150 primary providers were 
surveyed; 100 reported that they believed it was the responsibility of the mental health 
provider to test for MetS in psychiatric patients taking SGAs. Education of psychiatric 
providers, PCPS, and frontline nurses is imperative to understand the importance of 
screening, monitoring, and management of MetS (Cohn, 2013).  
Patients’ Barriers 
Failure to receive metabolic testing was most strongly associated with severity of 
psychiatric illness, patient characteristics such as cognitive dysfunction, lack of insight, 
judgment, delusions, hallucinations, paranoia and chronic mental illness (Morrato et al., 
2016). Patients may not be compliant with blood work, blood pressure checks, and 
height, weight and waist circumference measurement due to a lack of insight, poor 
judgment, delusions, hallucinations, and aggressive behavior. The mental health patients 
may lack the insight into the relationship between their mental and physical conditions, 
and as a result, may be less likely to recognize their symptoms and are less likely to seek 
medical help. 
Psychiatric Center’s Barriers 
Some mental health facilities are not equipped with resources needed to carry out 
the screening such as a weight scale, a blood pressure monitoring kit, and a tape measure. 
Munshi and colleagues (2015) indicated that another barrier hindering continuous 
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monitoring of MetS is the lack of integrated care between mental health and primary 
care. The patients often go from mental health provider to primary care, therefore 
incurring cost and at times may be lost in the healthcare system. Jeffery (2015) found out 
that limited access to primary PCPs and a poor referral system led to inadequate 
compliance by staff and patients in regard to lab work and any other recommendations. 
Most of the psychiatric patients are covered under Medicaid, with limited providers 
accepting patients with Medicaid, which increased their wait time for an appointment and 
thereby impeded continued monitoring. 
Guidelines for Management of Metabolic Syndrome 
According to Morrato and colleagues (2016), a decade ago, the American 
Diabetes Association (ADA), APA, American Association of Clinical Endocrinologists, 
and the North American Association for the Study of Obesity convened a conference on 
the subject of antipsychotic drugs and diabetes. The FDA established class warnings 
about an increased risk for hyperglycemia and diabetics with SGAs (Cotes et al., 2015). 
Around the same time, the ADA, APA, American Association of Clinical 
Endocrinologists, and North American Association for the Study of Obesity developed a 
consensus that recommended baseline screening and monitoring of metabolic risk for 
patients taking SGAs (Saloojeel et al., 2014; Cotes et al., 2015). The diagnosis of MetS 
included: increased waist circumference, raised blood pressure, increased triglycerides, 
decreased high-density lipoprotein (HDL) cholesterol and raised plasma glucose 
(Saloojeel et al., 2014). According to Ward and colleagues (2018), the guidelines 
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recommended that all patients prescribed antipsychotic medications should have 
metabolic screening completed every 3 months.  
Guidelines for Metabolic Monitoring 
According to Cotes and colleagues (2015) guidelines for the management of 
patients taking antipsychotic medications. The recommendations are, Baseline, 
assessment of personal, and family history, blood pressure, weight, waist circumference, 
fasting lipids, blood glucose,  
Measure weight at 4 weeks and 8 weeks 
Repeat labs at 12 weeks and yearly afterwards.  
The guideline outlines the frequency of screening and all the necessary 
monitoring parameters that will guide mental health providers for screening, monitoring, 
diagnosing and treating of MetS in patients taking antipsychotic medications especially 
SGAs. Early screening of patients will help meet the Institutes of Medicine (IOM) 
objectives for health improvement, which are safety, timeliness, efficiency, effectiveness, 
equitable and patient-centered care (IOM, 2016). 
The defining criteria for MetS is established by National Cholesterol Education 
Program Adult Treatment Panel (ATPIII) and IDF (Sulistiowati & Sihombing, 2016). 
The diagnosis of MetS is met when 3 of the 5 criteria; increased waist circumference, 
increased blood pressure, increased triglycerides, decreased high-density lipoprotein 
(HDL) cholesterol and raised plasma glucose are present in an individual (Saloojeel et al., 
2014). Once the diagnosis or risk factor is identified, appropriate treatment modality 
should be initiated. Treating both psychiatric disorders and MetS is imperative to enhance 
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better treatment outcomes for both conditions by referring patients to appropriate 
providers. As prescribers of antipsychotic medications, is imperative to be aware of 
specific psychotropic medications that raise the MetS risk more than others do and to be 
able to adapt the prescription of a particular medication to the cardiovascular risk profile 
of patients (Penninx & Lange, 2018). It is vital for nurses to educate predisposed 
psychiatric patients to MetS unhealthy lifestyle such as smoking, excessive alcohol intake 
and their contributions to poorer cardiovascular health and an increased risk of MetS.  
Follow-Up Monitoring for MetS 
According to Table 2, if abnormality is noted in any of the parameters, there are 
different treatment options to choose from; switch to a less risky agent, decrease the 
dosage of the medication, discontinue the medication, recommend healthy life style 
changes, and make referral for diabetes, lipid and weight management. Table 1 illustrated 
the recommended guidelines for baseline and continues monitoring of MetS. 
Local Background and Context 
The setting for the scholarly project is an in-patient urban psychiatric Center 
located in the Midwestern part of the country. The Center has three psychiatrists, three 
psychiatric nurse practitioners (NP), and many RNs. The hospital has other departments 
such as social work, psychology, and counseling. The medical director is a psychiatrist 
who oversees the clinical operations of the hospital and policy development. The 
psychiatrists and NPs are the ones that diagnose, treat, and discharge patients in this 
hospital. The setting is a 60-bed acute care psychiatric Center that treat adolescents, 
adults and seniors. The Center has discharges and admissions on a daily basis. On a 
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typical day; they discharge at least five patients and admit five new patients. The RNs are 
responsible for taking care of the patients on the unit. Most of the patients are low 
income, uninsured, underinsured, and rely on Medicaid coverage. The population seen in 
this psychiatric Center is diverse but predominantly from minority groups.  
The Center does not have any established protocol for monitoring MetS on 
patients that are taking antipsychotic medications. Regardless of the recommendations, 
metabolic disorders are still under-diagnosed and most of the time ineffectively treated in 
patients with mental illness (Munshi et al., 2015; Kioko et al., 2016). The prevalence of 
MetS among this population increased their risks of morbidity and mortality compared 
with the general population. According to Richardson, Lee. Kalarchian, & Ren, (2016), 
31% to 34% of the mentally ill population die from cardiovascular disease as a result of 
MetS. In a study of 50 psychiatric patients who were treated with SGAs, none of these 
patients had been previously screened for MetS by their psychiatrists even though 30% 
were positive for diabetes, 64.4% were diagnosed with hypertension, and 88% had 
increased cholesterol (Munshi et al., 2015). Adequate monitoring of MetS and its 
associated complication is necessary among psychiatric patients taking antipsychotic 
medications to reduce the occurrence of MetS.  
In this local psychiatric Center, a large number of patients on antipsychotic 
medications meet the criteria for MetS. One of the identified issues is lack of knowledge 
and who should monitor the MetS. The psychiatric providers are counting on the family 
practice to monitor for MetS. It is the providers’ responsibility for prescribing SGAs 
along with monitoring the metabolic abnormalities associated with the medications. The 
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goal of the educational intervention is to educate the psychiatric providers and nursing 
staff about the importance of early detection and intervention to alleviate these health 
problems associated with MetS.  
Role of the DNP Student 
It is a challenging and complicated process to bring evidence-based practice to 
clinical practice. The best quality evidence will be of no use unless incorporated into 
clinical practice. Improvement in healthcare outcomes and reduce cost of healthcare 
spending will be achieved with patients receiving evidence-based care. The 
organizational and systems leadership by nursing plays an integral part in the 
implementation of evidence-based practice in healthcare and is vital in creating an 
effective team to enhance the quality care and safety of their patients. As noted in AACN 
(2006), the mission of Walden University is to produce doctorally-prepared nurses with  
the knowledge and skills to positively lead the nursing profession in producing 
quality patient outcomes. The American Association of Colleges of Nursing (AACN, 
2006) endorsed a need to enhance knowledge to improve nursing practices and patient 
outcomes; this coincides with Walden’s social change, which implies that a positive 
social change results in the improvement of human and social conditions. Improved 
competencies for increasingly complex clinical, faculty, and leadership roles; advanced 
leadership skills, and clinical instruction by AACN (2006) coincides with Walden 
University visions of positive change in advancing greater global health. The scholarly 
project is aligned with the AACN (2006) goal and that DNP prepared nurses have the 
knowledge and skills to eliminate health disparities and to promote patient safety and 
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excellence in practice. The DNP graduates are able to assess risk and collaborate with 
others to manage risks ethically, based on professional standards. Adherence to mental 
health treatment will improve continuity and quality of care, which will lead to better 
patient outcomes, increased healthcare quality, and cost-effectiveness for the United 
States healthcare system. I hope to use the knowledge to influence positive patient 
outcomes in the field of psychiatry. The determination of the need for this educational 
intervention occurred through a needs assessment during my clinical rotation, which took 
place at the unit through collecting and reviewing data.  
At the same time, I wanted to understand the providers’ viewpoint of metabolic 
screening because, regardless of the agreed upon guideline. The rate of screening remains 
low and the long-term effects on patients’ health are being ignored. It was noted that the 
providers did not order baseline blood work; staff nurses do not obtain vital signs, weight, 
height and waist circumference prior to initiation of SGAs in psychiatric patients. I 
approached the chief nursing officer and the medical director, who is a psychiatrist, about 
the identified problem of not following the established MetS monitoring guideline in the 
Psychiatric Center. The overall goal of the DNP student was to educate the psychiatric 
providers about the relevance of MetS screening and monitoring in mentally ill patients 
taking antipsychotic medications. Early detection is vital to lower cardiovascular risk and 
to improve patient health outcomes. The DNP project intervention was to present 
education to psychiatric providers via PowerPoint with the objective of increasing their 
knowledge and identification of MetS in this vulnerable population for better health 
outcome.  
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Summary 
SGAs are used to manage different psychiatric conditions even though they have 
the tendency to cause weight gain, which predisposes patients to altered glucose and lipid 
metabolism leading to MetS. There is a globally recommended guideline for screening 
and monitoring of patients prescribed SGAs for MetS. Despite the screening and 
monitoring in Psychiatric Centers.  
The focus of this project was to educate providers and staff on using the best 
practice guideline that will improve the screening of patients on SGAs for MetS and to 
improve health outcomes of patients who have mental illness. According to the AACN 
(2006), “integration of these new or refined skills improves outcomes through 
organizational/systems leadership, quality improvement processes, and translation of 
evidence into practice (pp. 10). The DNP educational intervention supports nursing 
scholarship by initiating a change process in the organization based on research evidence. 
It integrated patient outcomes and safety as the driving forces in quality and patient 
satisfaction was aimed at education regarding the importance of screening and 
monitoring for MetS in patients taking SGAs in order to improve patient outcomes by 
closing the gap between evidence and implementation in a clinical setting. 
Section 3 will review the plan for collection and analysis of evidence.  
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Section 3: Collection and Analysis of Evidence 
Introduction 
SGAs are used in the treatment of mental disorders other than psychosis, such as 
bipolar, depression, and anxiety, because of fewer side effects associated with atypical 
antipsychotics. MetS is one of the undesirable side effects associated with antipsychotic 
medications. Regardless of the global consensus for screening and monitoring MetS, the 
rate of testing remains poor, despite the relationship between MetS and antipsychotic 
medications (Happell et al., 2016; Kioko et al., 2016; Munshi et al., 2015). In spite of 
best practice recommendations, psychiatrists practicing in this setting are not screening 
for MetS in their patients prescribed SGAs.  
The focus of the intervention was to improve the knowledge of healthcare 
providers on the metabolic guidelines for screening, early intervention, and treatment 
among psychiatric providers prescribing antipsychotic medications. The goal was to 
improve patient care by increasing the knowledge of providers and their adoption of best 
clinical practice guidelines for early detection and treatment of MetS in this vulnerable 
population. The practice-focused question was: Does an educational intervention for 
psychiatric providers prescribing psychiatric medications improve their knowledge and 
intent to adopt and implement metabolic screening guidelines in practice? Use of best 
practice guidelines should improve the screening rates and diagnosis/referral for MetS. 
Knowledgeable psychiatric nursing care will contribute to the adherence of patients in 
addressing self-care.  
29 
 
The goal of the educational intervention was to increase adherence to metabolic 
screening by healthcare providers. According to the National Health Service, brief 
educational interventions are a common method to engage nurse practitioners in thinking 
about ways to change their practice to improve health outcomes for patients (White, 
Hemingway, & Stephenson, 2014). The implementation of evidence-based metabolic 
screening will be the cornerstone for improving future care for psychiatric patients.  
Practice-Focused Question  
The project will improve the care provided to mentally ill patients taking 
antipsychotic medications by improving screening rates, diagnosis, and referral of MetS. 
The practice-focused question is: Does an educational intervention for psychiatric 
providers prescribing psychiatric medications improve their knowledge and intent to 
adopt and implement metabolic screening guidelines in practice?  
Program Design 
The purpose of the scholarly project was to educate and improve the knowledge 
of healthcare providers on the metabolic guidelines for screening, early intervention, and 
treatment for psychiatric patients prescribed SGAs. The education included an 
established screening tool from the Missouri Department of Mental Health for MetS (see 
Appendix F). The guideline outlined the frequency of screening and all the necessary 
monitoring parameters that will guide mental health providers in screening, monitoring, 
diagnosing, and treating MetS in patients taking SGAs. The project is not connected to 
patients directly. It is about educating healthcare providers on the use of the tool to 
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implement the treatments and reduce the MetS risk and subsequent diseases among 
patients with severe mental illness.  
The setting for the project was an in-patient acute care psychiatric center that 
targets an adult population. The population for this project was the psychiatric providers 
and registered nurses caring for mentally ill patients taking SGAs. Staff education was 
provided to healthcare providers that included three psychiatrists, three psychiatric nurse 
practitioners, and registered nurses. The staff were given the option to participate in the 
educational intervention (see Appendix A) and complete the pretest, posttest assessment 
(Appendix D) at the end of the intervention. Permission from Andrew Watkins to use the 
survey is shown in Appendix G. The pretest consisted of five multiple-choice questions 
about the content of the educational intervention and the questionnaire designed for the 
prescribers to solicit if they monitor their patients for metabolic abnormalities. An 
evaluation questionnaire was geared toward the importance of the education to their 
practice. At the end of the educational presentation, participants were required to 
complete the posttest, which was a duplication of the pretest and the post-evaluation 
survey (see Appendix E). 
Sources of Evidence 
Several databases were used for the literature review including MEDLINE, Pub 
Med, Psych INFO, Nursing, and Allied Health database, and CINAHL and Google 
Scholar. In reviewing literatures, particularly in patients taking antipsychotic 
medications, the keywords included, metabolic syndrome, antipsychotic medications, 
metabolic screening and mental illness, obesity, and diabetes. In other to meet the 
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inclusion criteria, the articles chosen for the project were published in English language, 
scholarly, peer reviewed journals within the last 5 years. For the literature review, a total 
of 30 articles were identified and examined. The providers and the nursing staff were 
taught by PowerPoint and verbal presentation about the prevalence, risk factors and 
implications of MetS in patients with mental illness. The education was delivered on-site 
to providers and nursing staff. Prior to the presentation, the educational flyer (see 
Appendix H) was disseminated to the healthcare staff via e-mails a week before the 
presentation. The educational intervention included information on the rationale for 
obtaining BMI, weight, height, required labs, and a referral to a PCP when patients are 
prescribed SGAs.  
Data Collection 
The data for the DNP project will be collected from the psychiatric providers 
using the pretest/posttest M-BACK questionnaire (Watkins et al., 2017) to evaluate the 
educational module for MetS risk factors, screening, monitoring, early intervention and 
referral for treatment. The M-BACK questionnaire is a reliable tool to measure 
practitioners’ barriers, knowledge and confidence regarding MetS screening in patients 
with mental illness (Watkins et al., 2017). The panel of experts are had over 10 years of 
experience in caring for psychiatric patients and they included a nurse educator, a nurse 
manager, two nurse practitioners and a psychiatrist. A comparison was made to determine 
the likelihood of the providers screening and monitoring for MetS in their clinical setting 
after attending the educational session. The surveys were anonymous and are being kept 
in a locked drawer.  
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Descriptive statistics were used in analyzing the data. The education was 
presented to the nursing staff during their staff meeting as recommended by the expert 
panel.  
Protections 
The educational session was held at a local psychiatric Center in the Midwest. 
There is no disclosure of the participating providers or their place of practice. A consent 
from the chief nursing officer for project implementation was obtained by me. Patients 
were not part of the project and there was no risk to healthcare providers attending the 
educational intervention. The psychiatric providers and the registered nurses had a choice 
to participate and complete the pretest, posttest and evaluation survey, which implied 
consent. The Walden University Institutional Review Board (IRB) approved the project 
(IRB approval # 05-21-19-0761020) prior to project implementation. There was no 
compensation for attending the educational session; rather, I provided snacks to the 
participants to show appreciation. The completed pretest, posttest, and evaluation surveys 
will be stored in accordance with IRB requirements and kept confidential in a locked box. 
Individual responses on the surveys were anonymous.  
Analysis and Synthesis 
The data from the survey were analyzed using descriptive analysis. The goal of 
the project was to educate the healthcare providers about the implementation of metabolic 
screening (MetS) based on current guidelines, including referring patients to primacy care 
providers for treatment of Mets if needed. A pretest and posttest were administered to 
providers to determine knowledge of metabolic screening guidelines before and after the 
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educational intervention. The pretest took at least 5 minutes to complete. A MetS 
pamphlet (see Appendix A) along with MetS screening tool was provided to participants 
based on established MetS screening guidelines. After the educational intervention, a post 
survey, which focused on the information presented in education and handout about MetS 
was provided to the participants. After collecting the pretest, the PowerPoint educational 
intervention (see Appendix I) was provided in a 30 minutes period succeeding a 15 
minutes period for questions and answers.  
Summary 
SGAs are widely used in the management of different psychiatric conditions 
because the medicines are effective in managing psychiatric symptoms with more 
tolerable side effects. However, antipsychotic medications have a weight gain tendency, 
which predisposes patient to altered glucose and lipid metabolism resulting in MetS. 
MetS is a combination of risk factors that put an individual at risk for cardiovascular 
diseases, which are the leading cause of premature death in the United States. There is a 
globally recommended guideline for screening and monitoring of patient on MetS. 
Despite the screening and monitoring guideline, there is a continued lack of screening 
and monitoring of patients taking antipsychotic medications in Psychiatric Center. The 
focus of this project was to develop recommended strategies to improve the screening of 
patients on antipsychotic medications for MetS and to improve health outcomes of 
patients who have mental illness. The educational intervention for providers about the 
importance of screening for MetS was cost-effectiveness as early identification and 
treatment of chronic diseases may avoid future complications and resulting costs. Section 
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4 describes the findings from the five expert panelists, and the findings and 
recommendations derived from the analysis of the educational project. 
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Section 4: Findings and Recommendations 
Introduction 
The local problem identified for this scholarly project was lack of adherence to 
practice guidelines for MetS screening and monitoring by psychiatric providers. The gap 
in practice was lack of metabolic monitoring and screening among psychiatric patients 
taking antipsychotic medications. Regardless of the global consensus for MetS screening 
and monitoring, and despite the relationship between MetS and SGAs, the rate of testing 
remains poor (Happell et al., 2016).  
The association between antipsychotic medications and MetS is complex. As the 
literature review revealed, MetS can lead to chronic diseases, such as heart disease and 
diabetes, which are responsible for seven out of 10 deaths among Americans each year 
and account for 75% of U.S. healthcare spending (CDC, 2017). The education will 
improve patient care by increasing the knowledge of providers and their adoption of best 
clinical practice guidelines for early detection and treatment of MetS in this vulnerable 
population. The purpose of this DNP project was to implement an educational 
intervention to educate healthcare providers about the importance of MetS among 
patients taking SGAs.  
Findings and Implications 
The setting for the scholarly project was an in-patient psychiatric center in the 
Midwest. The MetS toolkit (see Appendix F) was created to provide participants with a 
handout on critical information regarding MetS intervention. Five expert panelists were 
selected to review the educational content and provide feedback using a Likert-type 
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questionnaire. The selected five expert panelists chosen for the educational material 
review comprised of one psychiatrist, two psychiatric nurse practitioners, one nurse 
educator, and one charge nurse. The chosen panel of experts had over 10 years of 
experience in psychiatric mental health. The Likert-type questionnaire (see Appendix D) 
was used by the expert panelists in reviewing the educational contents. The questionnaire 
included five questions with the following answer options: strongly agree, agree, neutral, 
disagree, and strongly disagree. The sixth question was an open-ended question for 
comments or recommendations. 
The educational material (see Appendix I) was presented to the five panelists for 
their appraisal and recommendations. The expert panelists were given the opportunity to 
review the educational content for relevance to patient care and usefulness to the 
psychiatric center. The findings of the panelists indicated the contents about risks 
associated with MetS were easy for providers to understand, and the contents met the 
educational objectives (see Appendix B) of the project. The findings from the 
intervention resulted in the acceptance of the educational content by the panel of experts. 
The experts did not make any further recommendations.  
The educational intervention may result in improved outcomes for psychiatric 
patients taking SGAs. The organization may benefit by incorporating the education into 
annual staff training, which may lead to an increase in referrals for metabolic follow-up 
to other specialties of the organization if the program is successful. The major implication 
is the reduction in healthcare costs, prevention of chronic illnesses, and improvement in 
the quality of life for psychiatric patients. 
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Table 2 
 
Results of the Expert Panelist Questionnaire  
Questionnaire Item 
Response 
SA A N D SD 
Do the planned educational materials meet the 
objectives of the project? 
5 
100% 
    
The educational content is simplified for providers’ 
understanding. 
5 
100% 
    
Will the educational content improve providers’ 
knowledge about the importance of metabolic screening 
among psychiatric patients taking antipsychotic 
medications? 
5 
100% 
    
Will it be beneficial to make the education content part 
of providers’ annual training? 
5 
100% 
    
The measure of providers understanding of the 
education content will be measured by the outcomes of 
the posttest. 
5 
100% 
    
Note: N = 5; SA = strongly agree, A = agree, N = neutral, D = disagree, SD = strongly 
disagree 
 
Implementation 
A total of 12 participants attended the educational session presented to staff on 
MetS. The participants comprised of three psychiatrists, a psychiatric nurse practitioner, 
one nurse educator, six RNs, and one psychiatric technician. Both pretest and posttest 
questionnaires were identical and they used a 5-point Likert scale in which the 
participants were asked to circle the appropriate answer to indicate their chosen response 
to the questions. This process gave me the opportunity to determine the participants’ 
changes in knowledge before and after participating in the educational intervention. The 
staff members were informed that participation in the educational project was voluntary. 
Before the educational presentation, a pretest M-BACK Likert-type questionnaire (see 
Appendix D) was given to the participants, which took about 5 minutes to complete. 
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After collecting the pretest from the participants, the educational intervention was 
presented via PowerPoint presentation (see Appendix I). The presentation lasted about 30 
minutes and was followed by a period for questions and answers. The posttest 
questionnaire (see Appendix D) focusing on the educational information and making a 
change in practice, the MetS screening form (see Appendix F), and the ADA–APA 
consensus guidelines (see Appendix C) were provided to the participants. 
Table 3 
 
Pretest and Posttest Intervention Results about MetS, n =12, (in percentage)  
Question Pretest Posttest 
I have good knowledge of MetS. 8.3% 83.3% 
I understand how to screen for MetS. 16.7% 75.0% 
My work prevents me from doing any health promotion activities 
with consumers. 
33.3% 41.7% 
I understand the metabolic side effects profile of different 
neuroleptic medications. 
25.0% 66.7% 
Metabolic health screening is an important part of my role as a 
mental health clinician. 
25.0% 75.0% 
Note: N = 12 
 
Descriptive Data Analysis 
Upon reviewing the results of the data collected from the educational intervention 
of pretest and posttest. Based on the small sample size of the study, the result of the 
responses was entered in a table format. In observing the answers between the pretest and 
posttest to determine whether the answers changed after the educational program which 
shows a significant change. The following represents the presentation of the results and 
findings.  
Before the educational program, question #1 statement “I have good knowledge 
of MetS,” the pretest answers showed 8.3% of the participants strongly agreed. After the 
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educational intervention, the posttest showed 83.3% of the participants strongly agreed 
with the statement. The result showed the effectiveness of the educational intervention. 
Please refer to table 3 for comparison of the pretest and posttest scores. In response 
question 2 statement, “I understand how to screen for MetS? 16.7% of the participants 
strongly agreed before the educational intervention and 75.0% of the participants strongly 
agreed after the educational intervention. The third prompt related to whether their work 
prevented them from doing any health promotion activities with consumers. The 
responses on the pretest and posttest were similar with 33.3% of the participants agreeing 
before the educational intervention and 41.7% agreeing after the educational intervention. 
The question may have been confusing because it did not specify physical activity. If the 
participants perceived physical activity to be workout exercise, it would likely influence 
their responses. The responses may have resulted from lack of question clarity. The 
fourth prompt related to understanding the metabolic side effects profile of different 
neuroleptic medications. Based on the analysis, the overall response of the participants 
indicated an improvement in knowledge about metabolic side effect profiles after the 
educational intervention, with 25.0% strongly agreeing on the pretest and 66.7% strongly 
agreeing on post education. The fifth prompt related to the role of healthcare clinicians in 
metabolic screening. Based on the analysis, the participants’ knowledge improved about 
the importance of metabolic health screening as part of their roles. The pretest number of 
participants who strongly agreed with the statement improved from 25.0% to 75.0% on 
the posttest. The overall result showed the effectiveness of the educational intervention.  
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Implications to Positive Social Change 
According to Aselton, Joerg, and Affenito (2013), doctorate-prepared nurses 
(DNP) are in the position to influence health policies which will lead to a significant 
transformation in the healthcare system. One of the objectives of the clinical preventive 
services is to reduce the rate of disability, cost of healthcare, death and improve the 
health of the nation. The clinical preventive services are important to accomplish the 
“Healthy People” national the goal, which is promoting the health outcome of the nation. 
In alignment with the national calls for action and the need for health promotion and 
disease prevention, The DNP prepared nurses are in the position to utilize prevention and 
population health principles in inter-professional teams to effects health outcomes. The 
Psychiatric Center can use the project as a reference to develop providers’ annual training 
on MetS. It will lead to a greater awareness among nursing staff about the importance of 
monitoring for hypertension in each patient that attends the Psychiatric Center. The 
longer-term implication of the educational study is that monitoring of MetS in psychiatric 
patients taking anti-psychotic medications will prevent complications associated with 
MetS, improve patient the outcome, reduce healthcare cost, and finally impact positive 
social change in the field of psychiatry.  
Recommendations 
The outcome of the questionnaires strongly suggests that the educational 
intervention had an effect on the providers’ knowledge level and their willingness to 
screen for MetS on psychiatric patients taking antipsychotic medications. The registered 
nurses clearly understand their role and ability to help patients that may be at risk for 
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MetS by encouraging them to be compliant with lab draws, counseling them on physical 
activity and a healthy diet for weight. From the results of the DNP project, few 
recommendations for psychiatric providers in MetS screening and monitoring were 
noted. For all psychiatric providers working at the Psychiatric Center, educational 
programs specific to MetS screening and monitoring need to be provided annually to staff 
by the education department. This education needs to include not only screening and 
monitoring but also early intervention, collaboration, and referral to expert providers. 
Second, evidence-based guidelines and tools need to be adopted by the psychiatric 
providers to help manage MetS among these vulnerable population. This project shows 
that continuous education is critical for providers to be abreast with new research in 
healthcare for better patient outcomes. Third, the nursing staff should endeavor to obtain 
the necessary lab work and vital signs when ordered by the providers. Fourth, considering 
monotherapy once the risk factor is identified if a patient in on more than one 
antipsychotic medication, switching to medication with less weight gain profile.  
Strengths and Limitations of the project 
Strengths 
There are several strengths and limitations to my DNP scholarly project. One of 
the major strengths of the project is that the educational project was developed based on 
currently available evidence and established global consensus for the management of 
MetS among people with mental illness. One strength for the implementation of the 
educational project was the support from the frontline registered nurses who worked on 
the unit. The frontline nurses who participated in the educational intervention acquired 
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some knowledge about MetS which will affect their nursing practice in a positive 
manner.  
Limitations 
There were several limitations to this educational project which include, a 
convenience sample of 12 participants was utilized for the educational project; as a result, 
the conclusion cannot be generalized. According to Faber, & Fonseca (2014), a small 
sample size of 12 participants might not be able to be generalized to the general 
population. The posttests were given immediately after the intervention as well as the 
post survey. The data collected after the educational intervention represent the views of a 
specific group and not the entire providers in the hospital. There are several parameters to 
be evaluated for the metabolic screening which could lead to a poor result. The 
psychiatric providers that prescribe medications depend on the nurses or other healthcare 
workers to administer the screening tool. Button, Ioannidis, Morass, and Nosek (2013), 
found that a convenience sample of 12 participants will affect the reliability of the study. 
Summary 
Overall the staff felt that the educational program increased their knowledge 
about the screening and monitoring of MetS prior to taking the educational intervention. 
Prior to initiation of the educational project, the pretest questionnaires show significant 
variation in knowledge level psychiatric providers. After the educational program, 
psychiatric providers had the basic knowledge and understanding of the importance of 
screening psychiatric patients on antipsychotic medications for MetS. The educational 
project was first presented to five expert panels for feedback using the Likert-type 
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questionnaire. Then the education was presented to the psychiatric providers, the pre-and 
posttest intervention signified improved knowledge about the importance of MetS 
screening and its’ associated complications. Section 5 will include an analysis of self and 
the dissemination plan for the project outcome. 
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Section 5: Dissemination Plan 
Introduction 
The results of the educational project were positive and were disseminated to the 
medical staff of the hospital, which comprised of nurse practitioners, psychiatrists, and 
nursing staff. Based on the nature of the project, the appropriate audience for education 
were psychiatrists, psychiatric nurse practitioners, and RNs. Dissemination to this group 
of people was important to educate them to apply the evidence related to MetS in clinical 
practice for improving patient outcomes. I will offer a presentation to the leaders of the 
hospital and future presentation opportunities to present may arise as a result of the 
leadership presentation. Educational settings, such as conferences or in-services at a 
healthcare organization, would be appropriate for the dissemination of the project 
information about clinical practice adherence to a global consensus guideline. Finally, the 
ProQuest database is the avenue to disseminate the educational project for the broader 
nursing profession.  
Analysis of Self 
Obtaining a terminal degree in nursing will be fulfilling for me both personally 
and for my professional advancement. On a personal level, the scholarly project 
challenged my intellectual ability and fulfilled one of my long-term goals, which was to 
advance my nursing knowledge. Professionally, with the educational opportunity, I have 
enhanced my leadership skills and gained knowledge in advancing nursing practice, 
quality improvement, and healthcare policy.  
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Nurses are the key to improving quality and providing cost-effective care to 
enhance population health. As a practitioner and a scholar, prior to this project, my 
experience in leading a healthcare team in system change was limited. The scholarly 
project process provided me with the knowledge and skill sets to lead in any 
organizational change. Engaging the stakeholders and end users early in the project was 
the driving force that led to acceptance, assisted in achieving buy-in, and promoted 
commitment to the project. Before the implementation of any change, it is imperative to 
understand and identify the gap between recommended practice and the status quo. The 
completion of the assessment assisted me in identifying the actual and potential barriers 
to project implementation and the key staff who could assist to bridge the gap. After the 
project, I consider myself an expert in assessing organizational needs, identifying system 
issues, facilitating organization-wide changes in practice delivery, and assuming 
leadership roles in every level of nursing. 
Leadership 
It is well known that mental health services have been an area that has received 
less attention in medicine as compared to other health problems like cancer and 
cardiovascular disease. My goals as a practitioner and leader are to continue advocating 
for the integration of evidence-based practice and the global consensus for screening and 
monitoring MetS among psychiatric patients. I planned to continue advancing my 
profession by supporting research and creating a culture of evidence-based practice that 
will support clinical decision making. I planned to continue initiating change in the 
organization that is based on the research evidence and to integrate patient outcomes and 
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safety as a driving force in quality and patient satisfaction. The scholarly project gave me 
the perspective on the amount of work involved in project development and change in 
policy, the relationship between research and practice, and the time it takes for research 
results to be implemented in clinical practice. I planned to extend this project beyond my 
doctoral education by presenting to local psychiatric nurse practitioner organizations in 
the Midwestern part of the United States. 
The challenges I experienced with the project were time management, balancing 
project work, personal life, and my job. The solution I created for time management was 
allocating a specific time frame for school work with no interference. I feel self-discipline 
can be achieved by creating a schedule, managing time effectively, and developing an 
effective habit. Scheduling a specific time for staff education was challenging. The 
psychiatrists and the nursing staff were busy, the educational program took time away 
from patient care. The insights gained from the scholarly educational project was the 
amount of time and the dedication that goes into project development.  
Summary 
The purpose of this DNP project was to implement an educational intervention to 
educate healthcare providers the importance of MetS on patients taking SGAs at an In-
Patient Psychiatric Center in the Midwestern part of the U.S. I conducted a needs 
assessment in the Psychiatric Center, which indicated the gap-in-practice and lack of 
metabolic monitoring and screening among patients taking SGAs. Lack of monitoring for 
MetS increased the risk for the population served at the Psychiatric Center to develop 
chronic health problems; making it imperative for psychiatrists and nursing staff to 
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understand how to screen for MetS, manage, and refer as necessary. After the educational 
intervention, nurses gained basic knowledge and an understanding of the importance of 
metabolic screening. The project was effective as after the educational intervention, staff 
indicated their willingness to screen for MetS according to the established consensus 
guideline. Providers learned about the importance of screening for MetS and long-term 
cost-effectiveness will be attained through early identification and treatment of resulting 
chronic diseases, and avoidance of future complications and associated costs.  
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Appendix A: Metabolic Syndrome Pamphlet 
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Appendix B: Educational intervention Objectives 
Goal of the project: Is to provide psychiatric clinicians with knowledge about 
metabolic screening and monitoring of psychiatric patients taking antipsychotic 
medications and the need to reduce metabolic risk. This education can lead to 
improvement in the rate of screening and early intervention among this population.  
Target Audience: Psychiatrists, Psychiatric-Mental health NPs, psychiatric 
nurses, and Nurse Educators working with people with mental illness.  
Learning Objectives: 
1. Describe defining criteria of Metabolic syndrome and basic benefits of metabolic 
screening for patients taking antipsychotic medications.  
2. Describe the national established practice guideline for Metabolic screening and  
3. monitoring of patients taking antipsychotic medications, mainly second-generation 
antipsychotic (SGA) medications 
4. Describe the risk factors associated with metabolic syndrome. 
5. Describe gap in practice and barriers in implementation of metabolic screening 
6. in psychiatric patients on antipsychotic medications.  
7. Interprofessional Collaboration for improving patient and population health. 
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Appendix C: ADA–APA Consensus Guideline 
 Baseline 
screening 
4 
weeks  
8 
weeks  
12 
weeks  
Quarterly 
monitoring 
Annual 
monitoring 
Every 5 
years 
monitoring 
Personal/family 
history 
X     X  
Weight and 
height for 
calculation of 
BMI 
X X X X X   
Waist 
circumference 
at the level of 
the umbilicus 
X     X  
Blood pressure X   X  X  
Fasting plasma 
glucose 
X   X  X  
Fasting lipid 
profile 
X   X   X 
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Appendix D: Pretest/Posttest (M-BACK) Questionnaire 
Specialty Area: Please circle one specialty that identifies your profession.  
Psychiatrist       Psychiatric- NP     Nurse Educator    Psychiatric Nurse   Other ________     
 
1. I have a good knowledge of metabolic syndrome. 
 
  1                            2                    3                4                          5 
Strongly Disagree        Disagree       Neutral         Agree             Strongly Agree 
 
 
2. I understand how to screen for metabolic syndrome. 
 
  1                            2                    3                4                          5 
Strongly Disagree        Disagree       Neutral         Agree             Strongly Agree 
 
3. My workload prevents me doing any health promotion activities with consumers.  
  1                            2                    3                4                          5 
Strongly Disagree        Disagree       Neutral         Agree             Strongly Agree 
 
 
4. I understand the metabolic side-effect profiles of different neuroleptic medication. 
 
  1                            2                    3                4                          5 
Strongly Disagree        Disagree       Neutral         Agree             Strongly Agree 
 
 
5. Metabolic health screening is an important part of my role as a mental health clinician. 
 
  1                            2                    3                4                          5 
Strongly Disagree        Disagree       Neutral         Agree             Strongly Agree 
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Appendix E: Post Survey 
1. The educational materials about metabolic syndrome, do you plan to apply this in 
your job?  
2. Will you consider adopting a structured system for monitoring metabolic syndrome 
among patients on antipsychotic medications? 
3. Will you consider a collaborative relationship with family practice to facilitate care 
for patients on antipsychotic medications?  
4. Was the room temperature and lighting comfortable? 
5. Any other suggestion that should be included in the education of metabolic syndrome 
6. Any suggestion/comment  
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Appendix F: Metabolic Syndrome Screening Form 
Patient Name __________________________ Date of Visit ___________ 
Metabolic syndrome considered positive if 3 or more risk criteria present 
Measure Risk Criteria Baseline _/_/_ _/_/_ _/_/_ _/_/_ _/_/_ 
Abdominal 
Obesity 
 
Men  
>40 inches  
Women  
> 35 inches 
      
Triglycerides ≥150mg/dl       
HDL  
Cholesterol 
Men < 40 mg/dl 
Women < 50mg/dl  
      
Blood Pressure ≥ 130/≥85 mmHg       
Fasting lipid 
glucose  
≥ 100mg/dl       
Wt./BMI BMI ≥ 30       
 
Lipid Monitoring Results 
 Baseline  __/___/__ __/___/__ __/___/__ __/___/__ __/___/__ 
Total       
LDL       
HDL       
TG       
 
Serum Lipid Reference Range  
 Optimal/desired 
 
Near/above 
desired  
Borderline High Very high 
Total < 200  200-239 ≥ 240  
LDL < 100  
100-129 
130-159  ≥ 190 
HDL < 40 men 
< 50 women 
  ≥ 60  
TG < 150   150-199 200-499 ≥ 500 
www.cqaimh.org/pdf/tool_metabolic.pd 
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Appendix G: Approval Letter  
To whom it may concern, 
My name is Chika Okafor and I am a DNP student at Walden University, seeking 
permission to use your M-Back questionnaire from your article. I am only going to use 5 
questions. Could you please if I t is okay to use in my graduate project on educating 
psychiatric providers about the importance of metabolic screening in patients taking 
antipsychotic medications.  
Thank you in advance for your consideration 
Chika Okafor, MSN, ARNP, DNP Student, Walden University. 
From: Andrew Watkins (South Eastern Sydney LHD) 
<Andrew.Watkins@health.nsw.gov.au>  
Sent: Thursday, January 17, 2019 4:17 PM 
To: Okafor, Chika <Chika.Okafor@dmh.mo.gov> 
Subject: RE: The M-BACK Questionnaire 
Hi Chika, 
Great that you are doing some work in this area. I am happy for you to use the M-BACK, 
however, the M-BACK’s 16 question is divided into 4 sections Barriers, Attitudes, 
Confidence and Knowledge each with 4 questions. Each section is validated individually, 
but individual questions are not. I’m not sure which 5 questions you are using but it 
might not be considered validated. I would consider using 1 or 2 sections if you want to 
ensure that you are utilising a validated questionnaire. 
 I hope this is helpful, Kind regards 
Andrew Watkins, Clinical Nurse Consultant, Clinical lead 
Keeping the Body in Mind Program 
26 Llandaff St, Bondi Junction 2022 
9366 8610, https://www.seslhd.health.nsw.gov.au/keeping-body-min 
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Appendix H: Flyer for Training 
 
Presenter: Chika Okafor, DNP student, Walden University 
Join us 
Educating psychiatric providers about metabolic screening and 
intervention among patients on antipsychotic medications. 
 
Date: 6/3/19 Time: 5:00PM 
 
Venue: RPC Education Center 
 
Wow, refreshments will be provided 
For more information, contact: Chika Okafor @ 8164622218 
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Appendix I: Educational PowerPoint 
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